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This second issue of 2007 finally sees the publica-
tion of the first in a series of manuscripts dedicated
to the History of Oncology, with a special emphasis,
initially at least, on radio-therapeutics. Our European
editor, Dr. Richard Mould, writes the second-ever bi-
ography of the pioneering work of Pierre Curie (over-
shadowed to this day by the accomplishments of
Marie). Our apologies to Dr. Mould for the delay in
the appearance of this manuscript—intended for pub-
lication during the 2006 Pierre Curie centennial—in
part due to our reorganization and in part to a marked
increase in submissions to the journal. This history
series will continue through 2007.
When Dr. Laurie Elit and colleagues compared
treatment and survival in ovarian cancer over two
time periods in Ontario, they discovered that, although
age-standardized incidence and mortality rates for this
disease have remained stable, advances in manage-
ment have, it seems, led to a demonstrable improve-
ment in survival for those initially treated with
surgery. Their article lays out the data.
On another front, myeloma accounts for only
1.0% of the incidence of all malignancies, but for
approximately 13% of all hematologic neoplasms.
Until recently, the standard of care was melphalan
and prednisone, and although that treatment led to
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useful improvements in survival, few instances of
long-term remission were seen. Now, after nearly
40 years, new drug combinations are being explored,
and the goals of the MY.11 trial from the National
Cancer Institute of Canada Clinical Trials Group are
discussed in this issue.
Our Updates section includes two interesting re-
views. Professor Wen G. Jiang from the Metastasis
and Angiogenesis Research Group at the Wales Col-
lege of Medicine discusses hepatocyte growth factor
(HGF) and its receptor as potential therapeutic tar-
gets; he also raises awareness of the potential of HGF
as a molecular imaging tool. Similarly, rather than
being simple (and inert) tumour markers, it seems
that CEACAM5 (formerly CEA) and CEACAM6 may
represent targets for novel cancer therapies, includ-
ing cancer vaccines, cellular immunotherapy, radio-
immunotherapy, and antibody therapy as delineated
by Drs. Carlos Chan and Clifford Stanners from the
McGill Cancer Centre.
Finally, Dr. Steven Sagar and colleagues discuss
the potential benefits of massage therapy for cancer
patients. Their comprehensive review not only presents
the possible mechanisms of action that lead to the re-
ported benefits, but also appeals for the use of prospec-
tive studies to evaluate the magnitude of those benefits.